Cancer Drug Trial Leads Each Patient Into Remission

Cancer Drug Trial Leads Each Patient Into Remission

The risk of rectal cancer increases with age, leading to highly unpleasant issues like shortness of breath, abdominal pain, jaundice, chronic constipation, etc. Although the cause of this ailment is still unknown, one study has managed to make people dealing with this disease extremely happy since it reached a success rate of no less than an astounding 100%.

This small study included 12 patients with rectal cancer who took the same drug—dostarlimab. It’s designed to unmask cancer cells, making room for the immune system to recognize and eliminate them. The medication cost cca. $11,000 per dose and was administered for six months, every three weeks.

Much to everyone’s surprise, there was a remarkable absence of significant side effects. Generally, 1 in 5 patients have some type of adverse reaction to drugs similar to the one given to these patients. According to various experts, this could be the case either due to the insufficient number of people tested or the fact that these cancers are absolutely different.

The study is the first one to record a therapy that entirely eradicated cancer in each patient. While the results are more than promising, with every one of the patients experiencing the same incredible outcome, experts recommend the study be replicated in order to include a bigger number of patients.

It was initially planned for the treatment to be followed by common chemoradiotherapy and surgery. However, since all patients had a complete clinical response, with no evidence of tumor on all necessary evaluations, not a single patient had received any kind of follow-up treatment, and no cases of progression or recurrence had been noted up to that point.

Photo by National Cancer Institute on Unsplash

Leave a Comment

Your email address will not be published. *